Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSA-1002 in viral pneumonia ARDS
NCT06038916Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STSA-1002 in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Staidson Biopharmaceutical. Primary endpoint: Clinical remission time at Day 28. Started Dec 2023; status: completed.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06038916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038916.